TopicalDosed ingredient Cosmetic cross-reference

Brilliant Blue G

CAS 6104-58-1

Brilliant Blue G (CAS 6104-58-1) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral / FAERS

Adverse signals

SOURCE IUPHAR / PharmGKB

PubMed IDs

SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Brilliant Blue G

CAS Number

6104-58-1

UNII

M1ZRX790SI

InChIKey

RWVGQQGBQSJDQV-UHFFFAOYSA-M

ChEMBL ID

CHEMBL4173394

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredienttopical

SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL4173394 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE ChEMBL 36 activities + assays 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	5765.345454545455 nM	11	-
P2X purinoceptor 7 Ion channel	IC50	8	-	Homo sapiens
Alpha-synuclein Transporter	IC50	5.27	-	Homo sapiens
P2X purinoceptor 7 Ion channel	IC50	6.96	-	Mus musculus

SOURCE IUPHAR ligand-target interactions 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
P2X7 P2RX7	Antagonist	8.0 pIC50	10860929

SOURCE RxNorm drug names 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
BRILLIANT BLUE G	1998867	SU	MTHSPL
brilliant blue G	1998867	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Brilliant Blue G used for in pharmaceutical contexts?

Brilliant Blue G (CAS 6104-58-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Brilliant Blue G?

No adverse-event association or SIDER side-effect rows are rendered for Brilliant Blue G in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Brilliant Blue G also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for CI 42735 with EU status "restricted".

What clinical phase is Brilliant Blue G in?

Brilliant Blue G is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Brilliant Blue G?

Brilliant Blue G has 4 bioactivity rows in this page query. Rendered target entries include P2X purinoceptor 7, Alpha-synuclein.